RA Session II
2022
In 2022, RA Session II earned a total compensation of $2M as Former President, Chief Executive Officer and Director at Taysha Gene Therapies, a 57% decrease compared to previous year.
Compensation breakdown
| Bonus | $271,400 |
|---|---|
| Option Awards | $1,153,690 |
| Salary | $537,939 |
| Other | $173 |
| Total | $1,963,202 |
Session received $1.2M in option awards, accounting for 59% of the total pay in 2022.
Session also received $271.4K in bonus, $537.9K in salary and $173 in other compensation.
Rankings
In 2022, RA Session II's compensation ranked 1,776th out of 5,753 executives tracked by ExecPay. In other words, Session earned more than 69.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,776 out of 5,753 | 69th |
Division Manufacturing | 935 out of 3,133 | 70th |
Major group Chemicals And Allied Products | 378 out of 1,419 | 73rd |
Industry group Drugs | 346 out of 1,320 | 74th |
Industry Biological Products, Except Diagnostic Substances | 84 out of 291 | 71st |
Source: SEC filing on May 8, 2023.
Session's colleagues
We found three more compensation records of executives who worked with RA Session II at Taysha Gene Therapies in 2022.